Trials in Arizona.
64 APOE4-relevant Alzheimer’s trials run in Arizona — 31 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- General AD trial, no APOE4 focusNCT00265148Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
This Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Open to carriers, not 4-specificNCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Open to carriers, not 4-specificNCT03108846Escitalopram for Agitation in Alzheimer's Disease
This Phase 3 trial is testing whether escitalopram, a common antidepressant, can safely reduce agitation in people who already have Alzheimer's dementia. Phase…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Family history required, genotype not specifiedNCT04018092The Revitalize Study in Older Adults at Risk for Alzheimer's Disease
This trial is testing whether a light-based device — near-infrared light delivered through the scalp and nose, called photobiomodulation — can support brain…
- Open to carriers, not 4-specificNCT04148391NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Open to carriers, not 4-specificNCT04838301Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
This trial is testing allopregnanolone — a naturally occurring brain steroid — to see whether it slows or improves cognition in people with mild Alzheimer's…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Not relevant to most carriersNCT04920318Enhancing Language Function in Primary Progressive Aphasia
This trial is testing whether pairing a mild electrical brain stimulation technique called tDCS with standard language therapy works better than language…
- Open to carriers, not 4-specificNCT05399888A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…
- Observational registry, genotype not requiredNCT05405075Arizona Alzheimer's Disease Research Center (ADRC)
The Arizona ADRC is a research registry and data-collection program, not a drug or treatment trial. Participants — ranging from cognitively normal adults to…
- Not relevant to APOE4 carriersNCT05443633Enhancing Language Function in Aphasia
This trial is testing whether individualized speech-language training works better than standard language therapy for people with aphasia — a language…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, not 4-specificNCT05479552A Diagnostic Test for Dementia With Lewy Bodies
This study is testing a diagnostic tool called the Syn-One Test, which looks for a protein called alpha-synuclein in a skin biopsy. The goal is to better…
- Open to carriers, not 4-specificNCT05511363A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who…
- Open to carriers, ARIA risk appliesNCT05642429Study of AV-1959D, an Amyloid Beta Vaccine
This trial is testing AV-1959D, a vaccine designed to prompt the immune system to target amyloid beta — the protein that builds up in Alzheimer's disease. It…
- Not relevant to APOE4 or Alzheimer'sNCT05686551GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
This trial is testing tominersen, a drug injected into the spinal fluid, against a placebo in people with prodromal or early Huntington's Disease. The goal is…
- ARIA-focused — carriers often restrictedNCT05738486A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This Phase 3 trial is testing whether different dosing schedules of donanemab — an anti-amyloid antibody already conditionally approved — can reduce the rate…
- Exercise study, genotype not specifiedNCT05877196A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses
This trial is testing four different exercise programs, ranging from gentle stretching to high-intensity interval training, in older adults aged 65 and up who…
- Lifestyle study, genotype not requiredNCT05980052Goal Setting to Promote Physical Activity Adherence in Midlife Adults
This trial is testing different goal-setting strategies to help midlife adults stick to regular exercise routines. Researchers want to know which techniques…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Open to carriers, genotype not trackedNCT05988385The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
This trial is testing whether successfully treating moderate-to-severe obstructive sleep apnea (OSA) in older adults improves memory and changes biological…
- Open to carriers, not 4-specificNCT06126224A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
This Phase 3 trial is testing KarXT, a drug that targets muscarinic receptors in the brain, against a placebo in people aged 55 to 90 who have Alzheimer's…
- Open to carriers, not 4-specificNCT06223360A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's…
- Parkinson's trial, not APOE4-relevantNCT06263010Allopregnanolone as a Regenerative Treatment for Parkinson's Disease
This trial is testing allopregnanolone, a naturally occurring brain steroid, as a possible regenerative treatment for Parkinson's disease. Participants receive…
- Open to carriers, not 4-specificNCT06268886Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want…
- Open to carriers, genotype not trackedNCT06307574bpMedManage: Digital Technology to Support Adherence to Hypertension Medications
This trial is testing a smartphone app designed to help older adults with mild cognitive impairment stick to their blood pressure medications. One group gets…
- Unrelated to APOE4 or dementiaNCT06516965A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
This Phase 3 trial is testing povorcitinib, a JAK inhibitor pill, against a placebo in people with prurigo nodularis — a chronic skin condition causing intense…
- Open to carriers, not 4-specificNCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
This trial is testing whether a drug called JNJ-64042056 can slow the spread of tau protein in the brain, measured by PET scan. It enrolls people who already…
- Open to carriers, not 4-specificNCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…
- Anti-amyloid combo — carriers face higher ARIA riskNCT06602258A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing whether a drug called E2814, given alongside the already-known anti-amyloid drug lecanemab, can reduce a tau protein marker…
- Behavioral study, genotype not requiredNCT06649929Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples With Implications for Alzheimer's Disease Risk
This trial tests a couples-based coaching program called Nuestro Sueno, designed specifically for Latino couples where one partner has been diagnosed with…
- Unrelated to APOE4 or Alzheimer'sNCT06667414Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
This study is mapping specific genetic markers called SNPs in people who carry the Huntington's disease gene mutation. Participants give a blood sample and…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.